Skip to main content
. 2018 Nov 26;10(1):103–110. doi: 10.1111/1759-7714.12917

Table 1.

Demographics of EGFR, ALK, and ROS1 status in 407 NSCLC consecutive patients

EGFR (n = 106) ALK (n = 19) ROS1 (n = 14)
Variables Total N (%) P N (%) P N (%) P
Age, mean ± SD 66.9 ± 12.07 64.8 ± 12.0 0.033 55.7 ± 15.7 < 0.001 61.2 ± 15.5 < 0.001
Gender, N (%)
Male 238 (58.6) 29 (27.4) < 0.001 7 (36.8) 0.058 4 (28.6) 0.026
Female 168 (41.4) 77 (72.6) 12 (63.2) 10 (71.4)
Smoking history
Never smoker 183 (46.4) 76 (73.8) < 0.001 14 (73.7) 0.018 10 (71.4) 0.098
Ever smoker 211 (53.6) 27 (26.2) 5 (26.3) 4 (28.6)
Packyears 19.5 ± 23.6 5.5 ± 11.6 < 0.001 6.9 ± 14.8 0.001 12.1 ± 24.3 0.237
Histology
ADC 306 (75.4) 101 (95.3) < 0.001 § 17 (89.5) 0.179 § 14 (100) 0.026 §
SCC 74 (18.2) 4 (3.8) 1 (5.3) 0 (0.0)
ADSQ 9 (2.2) 1 (0.9) 0 (0.0) 0 (0.0)
Other NSCLCs 17 (4.2) 0 (0.0) 1 (5.3) 0 (0.0)
Stage
IA 60 (15.2) 20 (19.6) < 0.001 2 (10.5) 0.006 1 (7.1) 0.001
IB 37 (9.4) 10 (9.8) 0 (0.0) 1 (7.1)
IIA 18 (4.6) 7 (6.9) 1 (5.3) 0 (0.0)
IIB 18 (4.6) 2 (2.0) 1 (5.3) 1 (7.1)
IIIA 38 (9.6) 7 (6.9) 2 (10.5) 0 (0.0)
IIIB 32 (8.1) 6 (5.9) 0 (0.) 0 (0.0)
IV 191 (48.5) 50 (49.0) 13 (68.4) 11 (78.6)
Type of sample
Biopsy 0.258†† 1.000†† 1.000††
Bronchoscopy 42 (10.3) 6 (5.7) 3 (15.8) 1 (7.1)
PCNB 298 (73.4) 87 (82.1) 13 (68.4) 9 (64.3)
Metastatic site 35 (8.7) 7 (6.6) 3 (15.8) 3 (21.4)
Cell block 5 (1.2) 3 (2.8) 0 (0.0) 1 (7.1)
EBUS‐TBNA 10 (2.5) 1 (0.9) 0 (0.0) 0 (0.0)
Surgical resection
Lobectomy 13 (3.2) 2 (1.9) 0 (0.0) 0 (0.0)
Wedge resection 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0)

P value was evaluated compared to wild type for the gene.

Evaluated by t‐test.

§

Adenocarcinoma versus all others.

Stage I–IIIa versus IIIb–IV.

††

Biopsy versus surgical resection.

Values in bold are statistically significant.

ADC, adenocarcinoma; SCC, squamous cell carcinoma; ADSQ, adeno‐squamous carcinoma; NSCLC, non‐small cell lung cancer; PCNB, percutaneous needle aspiration biopsy; EBUS‐TBNA, endobronchial ultrasound‐transbronchial needle aspiration biopsy.